Journal
JOURNAL OF PHARMACEUTICAL SCIENCES
Volume 100, Issue 1, Pages 38-52Publisher
ELSEVIER SCIENCE INC
DOI: 10.1002/jps.22243
Keywords
biotechnology; cationic lipids; DNA/oligonucleotide delivery; encapsulation; gene delivery; gene vectors; lipoplexes; macromolecular drug delivery; nanoparticles; nonviral gene delivery
Funding
- NIBIB NIH HHS [R01 EB005476, R01 EB005476-01A2] Funding Source: Medline
- NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB005476] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The ability to deliver nucleic acids (e. g., plasmid DNA, antisense oligonucleotides, siRNA) offers the potential to develop potent vaccines and novel therapeutics. However, nucleic acid-based therapeutics are still in their early stages as a new category of biologics. The efficacy of nucleic acids requires that these molecules be delivered to the interior of the target cell, which greatly complicates delivery strategies and compromises efficiency. Due to the safety concerns of viral vectors, synthetic vectors such as liposomes and polymers are preferred for the delivery of nucleic acid-based therapeutics. Yet, delivery efficiencies of synthetic vectors in the clinic are still too low to obtain therapeutic levels of gene expression. In this review, we focus on some key issues in the field of nucleic acid delivery such as PEGylation, encapsulation and targeted delivery and provide some perspectives for consideration in the development of improved synthetic vectors. (C) 2010 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 100:38-52, 2011
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available